These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 34098292)
1. The impact of COVID-19 on opioid treatment program (OTP) services: Where do we go from here? Tracy K; Wachtel L; Friedman T J Subst Abuse Treat; 2021 Dec; 131():108394. PubMed ID: 34098292 [TBL] [Abstract][Full Text] [Related]
2. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership. Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636 [No Abstract] [Full Text] [Related]
3. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19. Brothers S; Viera A; Heimer R J Subst Abuse Treat; 2021 Dec; 131():108449. PubMed ID: 34098303 [TBL] [Abstract][Full Text] [Related]
4. The impact of COVID-19 on opioid treatment programs in the United States. Goldsamt LA; Rosenblum A; Appel P; Paris P; Nazia N Drug Alcohol Depend; 2021 Nov; 228():109049. PubMed ID: 34600258 [TBL] [Abstract][Full Text] [Related]
6. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic. Cochran G; Bruneau J; Cox N; Gordon AJ Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171 [TBL] [Abstract][Full Text] [Related]
7. Loss, liberation, and agency: Patient experiences of methadone treatment at opioid treatment programs during the COVID-19 pandemic. López-Castro T; Jakubowski A; Masyukova M; Peterson M; Pierz A; Kodali S; Arnsten JH; Starrels JL; Nahvi S J Subst Use Addict Treat; 2024 Feb; 157():209235. PubMed ID: 38061636 [TBL] [Abstract][Full Text] [Related]
8. Assessing the impact of social distancing measures implemented during COVID-19 pandemic on medications for opioid use disorder in West Virginia. Haggerty T; Khodaverdi M; Dekeseredy P; Wood N; Hendricks B; Peklinsky J; Sedney CL J Subst Abuse Treat; 2022 May; 136():108687. PubMed ID: 34903397 [TBL] [Abstract][Full Text] [Related]
10. TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19. Pena E; Ahmed S Addiction; 2020 Oct; 115(10):1978-1979. PubMed ID: 32447795 [No Abstract] [Full Text] [Related]
11. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic. Hughes PM; Verrastro G; Fusco CW; Wilson CG; Ostrach B J Rural Health; 2021 Jun; 37(3):467-472. PubMed ID: 33720447 [TBL] [Abstract][Full Text] [Related]
13. Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19. Joseph G; Torres-Lockhart K; Stein MR; Mund PA; Nahvi S J Subst Abuse Treat; 2021 Mar; 122():108219. PubMed ID: 33353790 [TBL] [Abstract][Full Text] [Related]
14. Methadone Access for Opioid Use Disorder During the COVID-19 Pandemic Within the United States and Canada. Joudrey PJ; Adams ZM; Bach P; Van Buren S; Chaiton JA; Ehrenfeld L; Guerra ME; Gleeson B; Kimmel SD; Medley A; Mekideche W; Paquet M; Sung M; Wang M; You Kheang ROO; Zhang J; Wang EA; Edelman EJ JAMA Netw Open; 2021 Jul; 4(7):e2118223. PubMed ID: 34297070 [TBL] [Abstract][Full Text] [Related]
15. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic. Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894 [TBL] [Abstract][Full Text] [Related]
16. Patient experiences of COVID-19-induced changes to methadone treatment in a large community-based opioid treatment program in Baltimore. Abidogun TM; Cole TO; Massey E; Kleinman M; Greenblatt AD; Seitz-Brown CJ; Magidson JF; Belcher AM J Subst Use Addict Treat; 2023 Feb; 145():208946. PubMed ID: 36880915 [TBL] [Abstract][Full Text] [Related]
17. Improving methadone access for rural communities in the USA: lessons learned from COVID-19 adaptations and international models of care. Lister JJ; Lister HH Rural Remote Health; 2021 Nov; 21(4):6770. PubMed ID: 34757760 [TBL] [Abstract][Full Text] [Related]
18. In-Hospital Methadone Enrollment: a Novel Program to Facilitate Linkage from the Hospital to the Opioid Treatment Program for Vulnerable Patients with Opioid Use Disorder. Calcaterra SL; Saunders S; Grimm E; Maki-Gianani E; Keniston A; Wold A; Bonaguidi A J Gen Intern Med; 2024 Feb; 39(3):385-392. PubMed ID: 37715094 [TBL] [Abstract][Full Text] [Related]
19. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic. Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198 [TBL] [Abstract][Full Text] [Related]
20. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade? Nunes EV; Levin FR; Reilly MP; El-Bassel N J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]